ReviewMarine drugs2017
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.
Review in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated CyanobacteriumJournal of natural products · 2025Article
- Polymer-DNA assembled nanoflower for targeted delivery of dolastatin-derived microtubule inhibitors.RSC advances · 2024Article
- Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review.Cancer metastasis reviews · 2024Review
- Genomes of nine biofilm-forming filamentous strains of Cyanobacteria (generaFEMS microbes · 2024Article
- Marine Compounds, Mitochondria, and Malignancy: A Therapeutic Nexus.Marine drugs · 2022Review
- Natural product-based radiopharmaceuticals: Focus on curcumin and its analogs, flavonoids, and marine peptides.Journal of pharmaceutical analysis · 2022Review
- Aulosirazoles B and C from the CyanobacteriumJournal of natural products · 2022Article
- Biomaterials from the sea: Future building blocks for biomedical applications.Bioactive materials · 2021Review
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- Heterologous Expression of Cryptomaldamide in a Cyanobacterial Host.ACS synthetic biology · 2020Article
- Recent advances in the synthesis of C-terminally modified peptides.Organic & biomolecular chemistry · 2020Review
- Dolastatin 15 from a Marine Cyanobacterium Suppresses HIF-1α Mediated Cancer Cell Viability and Vascularization.Chembiochem : a European journal of chemical biology · 2020Article
- Chemistry of Renieramycins. Part 19: Semi-Syntheses of 22-Marine drugs · 2020Article
- Natural Bioactive Thiazole-Based Peptides from Marine Resources: Structural and Pharmacological Aspects.Marine drugs · 2020Review
- Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets.Molecules (Basel, Switzerland) · 2020Review
- Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.Natural product reports · 2020Review
- Shellmycin A-D, Novel Bioactive Tetrahydroanthra-γ-Pyrone Antibiotics from MarineMarine drugs · 2020Article
- Enriching cancer pharmacology with drugs of marine origin.British journal of pharmacology · 2020Review
- Resistance and Overcoming Resistance in Breast Cancer.Breast cancer (Dove Medical Press) · 2020Review
- Origins and Bioactivities of Natural Compounds Derived from Marine Ascidians and Their Symbionts.Marine drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we have attempted to describe all of the antibody-drug conjugates using a marine-derived compound as the "warhead", that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the beta-test version currently available, as it permitted more specific search parameters, since the regular version did not always find trials that had been completed in the past with some agents. We also added small discussion sections on candidates that are still at the preclinical stage, including a derivative of diazonamide that has an unusual interaction with tubulin (DZ-23840), which may also be a potential warhead in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.